Workflow
cept Therapeutics rporated(CORT)
icon
Search documents
cept Therapeutics rporated(CORT) - 2023 Q1 - Earnings Call Transcript
2023-05-04 03:43
Call Start: 17:00 January 1, 0000 5:41 PM ET Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2023 Earnings Conference Call May 3, 2023 17:00 ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Bill Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann David Amsellem - Piper Sandler Edward Nash - Canaccord Genuity Roanna Ruiz - SVB Securities Greg Fraser - Truist Operator G ...
cept Therapeutics rporated(CORT) - 2023 Q1 - Quarterly Report
2023-05-02 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS ...
cept Therapeutics rporated(CORT) - 2022 Q4 - Earnings Call Transcript
2023-03-01 00:59
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Bill Guyer - Chief Development Officer Sean Maduck - President of Endocrinology Division Conference Call Participants Raymond Wu - Ladenburg Thalmann Dennis Ding - Jefferies Greg Fraser - Truist Arthur He - H.C. Wainwright Operator Greetings, and welcome to the ...
cept Therapeutics rporated(CORT) - 2022 Q4 - Annual Report
2023-02-27 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS INCORPORATED (Exact Name of Corporation as Specified in Its Charter) Delaware 77-0487658 (State or other jurisdictio ...
cept Therapeutics rporated(CORT) - 2022 Q3 - Earnings Call Transcript
2022-11-04 03:11
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Joseph Belanoff - CEO and President Atabak Mokari - CFO Bill Guyer - CDO Charlie Robb - CBO Sean Maduck - President, Corcept Endocrinology Conference Call Participants Ed Nash - Canaccord Dennis Ding - Jefferies Greg Fraser - Truist Alan Leong - BioWatch News Operator Good day, and thank you for standing by. Welcome to the Corcept Therapeutics Conference Call. At this time, all p ...
cept Therapeutics rporated(CORT) - 2022 Q3 - Quarterly Report
2022-11-02 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 ________________ ...
cept Therapeutics rporated(CORT) - 2022 Q2 - Earnings Call Transcript
2022-08-04 02:23
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Joseph Belanoff - Chief Executive Officer, President, and Director Atabak Mokari - Chief Financial Officer Bill Guyer - Chief Development Officer Charlie Robb - Chief Business Officer Sean Maduck - President, Corcept Endocrinology Conference Call Participants Matt Kaplan - Ladenburg Thalmann & Co. Inc. Dennis Ding - Jefferies Greg Fraser - Truist Securities Arthur He - H.C. Wainwr ...
cept Therapeutics rporated(CORT) - 2022 Q2 - Quarterly Report
2022-08-03 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 _____________________ ...
cept Therapeutics rporated(CORT) - 2022 Q1 - Earnings Call Presentation
2022-05-13 18:48
May 2022 Safe Harbor This presentation contains forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended, and the Securities Act of 1933, as amended. All statements contained in this presentation other than statements of historical fact are forward-looking statements. When used in this presentation or elsewhere by management from time to time, the words "believe," "anticipate," "intend," "plan," "estimate," "expect," "may," "will," "should," "seeks" and similar expres ...
cept Therapeutics rporated(CORT) - 2022 Q1 - Earnings Call Transcript
2022-05-06 02:48
Corcept Therapeutics Incorporated. (NASDAQ:CORT) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Sean Maduck - Chief Commercial Officer Bill Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Chris Howerton - Jefferies Edward Nash - Canaccord Genuity Gregory Fraser - Truist Securities Arthur He - H.C. Wainwright Alan Leong - ...